Page last updated: 2024-11-07

verrucarol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Verrucarol is a mycotoxin produced by various Fusarium species, including Fusarium tricinctum and Fusarium sporotrichioides. It is a sesquiterpene lactone with potent cytotoxic and immunosuppressive activities. Verrucarol has been implicated in various health issues, including food poisoning and animal diseases. Its synthesis involves a complex biosynthetic pathway involving several enzymes. Verrucarol's cytotoxic effects are attributed to its ability to inhibit DNA and RNA synthesis, leading to cell death. Its immunosuppressive properties stem from its ability to interfere with the immune system's signaling pathways. Studies on verrucarol focus on its potential for therapeutic applications, such as anticancer and antifungal agents. However, its toxicity limits its clinical use. The study of verrucarol is crucial to understand its potential risks and benefits, and to develop strategies for its mitigation and potential therapeutic applications.'

Cross-References

ID SourceID
PubMed CID104989
MeSH IDM0057222

Synonyms (6)

Synonym
SMP2_000068
verrucarol
2198-92-7
trichothec-9-ene-4,15-diol, 12,13-epoxy-, (4.beta.)-
DTXSID00891793
(2r,7r,9r,11r)-2-(hydroxymethyl)-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-11-ol

Research Excerpts

Overview

Verrucarol is a simple trichothecene which is structurally related to T-2 and HT-2 toxins.

ExcerptReferenceRelevance
"Verrucarol is a simple trichothecene which is structurally related to T-2 and HT-2 toxins. "( Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs.
Barel, S; Bialer, M; Yagen, B, 1990
)
1.98

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life of verrucarol calculated from the urinary data of its conjugated metabolites was not significantly different from the half-life calculated from the plasma data of the parent compound."( Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs.
Barel, S; Bialer, M; Yagen, B, 1994
)
0.89

Bioavailability

ExcerptReferenceRelevance
" Following oral administration, the absolute bioavailability of verrucarol was 44 +/- 33%, and its terminal half-life was similar to that obtained after iv administration."( Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs.
Barel, S; Bialer, M; Yagen, B, 1990
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (41.67)18.7374
1990's3 (25.00)18.2507
2000's3 (25.00)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.80 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]